Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS + HIPEC After Preoperative Chemotherapy in Gastric Cancer Peritoneal Carcinomatosis
DRKS00003078Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, oxaliplatin, capecitabine, cisplatin, trastuzumab and 1 more in gastric cancer (GC), Esophago-Gastric Adenocarcinoma and peritoneal carcinomatosis (PC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2011; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)Esophago-Gastric Adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on DRKS00003078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003078.